Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

The first quarter of 2025 was a tough one. The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%. Following the trend, ...

Moderna shares may remain under the microscope on Tuesday after sinking to a five-year low following news that the Food and Drug Administration’s top vaccine official has resigned. Watch these key ...

Leerink Partners analyst David Risinger maintained a Sell rating on Moderna (MRNA – Research Report) yesterday and set a price target of ...

We recently published a list of Jim Cramer Says Wait A Little & Discusses These 11 Stocks. In this article, we are going to ...

However, in the later stages of the pandemic, demand for the product declined, and Moderna shifted to a loss. For example, last year, the company brought in $3.2 billion in revenue, compared to more ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various ...

US mRNA specialist Moderna (Nasdaq: MRNA) has announced that its manufacturing facility in the UK has been granted a manufacturer’s license by the Medicines and Healthcare products Regulatory Agency ...

Moderna Inc MRNA -11.5% Get Free Report shares were down 13.5% at $26.88 and Novavax Inc NVAX -9.02% Get Free Report shares were down 9.6% at $6.30 at last check. The SPDR S&P Biotech ETF XBI -4.88% + ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

The most recent trading session ended with Moderna (MRNA) standing at $24.73, reflecting a -1.85% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's daily ...